Homology Medicines, Inc. (FIXX)
(Delayed Data from NSDQ)
$22.32 USD
+0.63 (2.90%)
Updated May 3, 2019 04:00 PM ET
After-Market: $22.27 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$22.32 USD
+0.63 (2.90%)
Updated May 3, 2019 04:00 PM ET
After-Market: $22.27 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Homology Medicines (FIXX) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Homology Medicines (FIXX) delivered earnings and revenue surprises of 9.09% and 40.59%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Generation Bio Co. (GBIO) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Generation Bio Co. (GBIO) delivered earnings and revenue surprises of -35.90% and 100%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Amphastar Pharmaceuticals (AMPH) Tops Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Amphastar (AMPH) delivered earnings and revenue surprises of 37.78% and 7.30%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
BridgeBio Pharma (BBIO) Moves 9.7% Higher: Will This Strength Last?
by Zacks Equity Research
BridgeBio Pharma (BBIO) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Homology Medicines (FIXX) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Homology Medicines (FIXX) delivered earnings and revenue surprises of -17.65% and 23.62%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Supernus Pharmaceuticals (SUPN) Q4 Earnings and Revenues Lag Estimates
by Zacks Equity Research
Supernus (SUPN) delivered earnings and revenue surprises of -41.10% and 8.15%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
BridgeBio Pharma (BBIO) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
BridgeBio Pharma (BBIO) delivered earnings and revenue surprises of -1.16% and 84.72%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Homology Medicines (FIXX) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Homology Medicines (FIXX) delivered earnings and revenue surprises of -25.53% and 23.62%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
SolGel Technologies Ltd. (SLGL) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
SolGel Technologies Ltd. (SLGL) delivered earnings and revenue surprises of -114.29% and 92.44%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Supernus Pharmaceuticals (SUPN) Misses Q3 Earnings Estimates
by Zacks Equity Research
Supernus (SUPN) delivered earnings and revenue surprises of -90.63% and 2.39%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Amphastar Pharmaceuticals (AMPH) Q3 Earnings Meet Estimates
by Zacks Equity Research
Amphastar (AMPH) delivered earnings and revenue surprises of 0% and 4.81%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Homology Medicines (FIXX) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Homology Medicines (FIXX) delivered earnings and revenue surprises of 10.53% and 23.62%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Bausch Health (BHC) Q2 Earnings and Revenues Miss Estimates
by Zacks Equity Research
Bausch (BHC) delivered earnings and revenue surprises of -38.20% and 3.84%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Amphastar Pharmaceuticals (AMPH) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Amphastar (AMPH) delivered earnings and revenue surprises of 5.41% and 4.49%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
SolGel Technologies Ltd. (SLGL) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
SolGel Technologies Ltd. (SLGL) delivered earnings and revenue surprises of 90% and 27.46%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Homology Medicines (FIXX) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Homology Medicines (FIXX) delivered earnings and revenue surprises of 20% and 38.31%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
SolGel Technologies Ltd. (SLGL) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
SolGel Technologies Ltd. (SLGL) delivered earnings and revenue surprises of 20% and 99.85%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Homology Medicines (FIXX) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Homology Medicines (FIXX) delivered earnings and revenue surprises of -1.72% and 19.80%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Here's Why Homology Medicines (FIXX) Looks Ripe for Bottom Fishing
by Zacks Equity Research
After losing some value lately, a hammer chart pattern has been formed for Homology Medicines (FIXX), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
Why Homology Medicines (FIXX) Might Surprise This Earnings Season
by Zacks Equity Research
Homology Medicines (FIXX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Homology Medicines (FIXX) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
by Zacks Equity Research
Homology Medicines (FIXX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
BridgeBio Pharma (BBIO) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
BridgeBio Pharma (BBIO) delivered earnings and revenue surprises of -21.69% and 61.18%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Here's Why Homology Medicines (FIXX) is Poised for a Turnaround After Losing 25.1% in 4 Weeks
by Zacks Equity Research
Homology Medicines (FIXX) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Is Assertio (ASRT) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Assertio (ASRT) and Homology Medicines (FIXX) have performed compared to their sector so far this year.
Supernus (SUPN) Moves 5.7% Higher: Will This Strength Last?
by Zacks Equity Research
Supernus (SUPN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.